RDD Blog » 2009 » January

R&D Directions Insider

Archive for January, 2009

Stem cells charge ahead

Friday, January 30th, 2009

If you want to jump into the stem cell research debate, this is the time to do it. The plot has indeed thickened. Just three days after a new administration took the reins in Washington, FDA approved the first ever clinical trial of a therapy derived from human embryonic stem ...

Posted in Uncategorized | No Comments »

R&D Directions survey: Novartis pipeline the most admired

Wednesday, January 28th, 2009

Novartis has won R&D Directionsâ€™ Most Admired Pipeline Survey, beating out 24 of its big-pharma competitors in a poll of clinical-trial experts in industry and academia. With words like â€œbreadthâ€ and â€œdepthâ€ and â€œdiversityâ€ and â€˜robustâ€ being used to describe its pipeline, Novartis garnered 20.2% of the total vote, or 68 ...

Posted in Uncategorized | No Comments »

Will bigger be better?

Monday, January 26th, 2009

Chalk another one up to the â€œtiming is everythingâ€ argument. On the same morning Pfizer announced a 90% profit fall in fourth-quarter 2008 and a slight drop in full-year â€™08 revenues, the drug giant pulled the proverbial rabbit from the hat for all to see. As The New York Times ...

Posted in Uncategorized | 1 Comment »

Itâ€™s official: Pfizer buying Wyeth

Monday, January 26th, 2009

Well, that didnâ€™t take long. News leaked Friday that the gargantuan deal might be possible. Just one business day later, itâ€™s a reality. Both companies confirmed today that they have entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction totaling about $68 billion, ...

Posted in Uncategorized | No Comments »

Is Pfizer courting Wyeth?

Friday, January 23rd, 2009

That's the $60 billion dollar question. Youâ€™ve heard the buzz by now, Pfizer, according to a scoop by The Wall Street Journal, is apparently negotiating to buy Wyeth in a deal that could top more than $60 billion. While the report noted nothing is imminent and talks could collapse at ...

Posted in Uncategorized | No Comments »

Social networking meets patient recruitment

Wednesday, January 21st, 2009

Finally, a more practical reason to go on Facebook than to just see pictures of my seventh-grade lab partner's new pet schnauzer. This week, Acurian Inc., a patient recruitment provider, launched a new social networking application for clinical trial awareness called Click it Forward. The Horsham, Pa.-based company developed the ...

Posted in Uncategorized | 1 Comment »

Hard science

Friday, January 16th, 2009

Wow, being a scientist in the pharmaceutical industry is a tough gig these days. And weâ€™re not even talking about the science part. Pfizerâ€™s announcement this week that it is axing up to 800 researchers as part of further â€œrefocusingâ€ efforts is just further proof that job security for scientists ...

Posted in Uncategorized | 1 Comment »

©2012 UBM Canon